Acumen Pharmaceuticals Inc (ABOS)vsAstraZeneca PLC (AZN)
ABOS
Acumen Pharmaceuticals Inc
$2.11
-7.46%
HEALTHCARE · Cap: $161.07M
AZN
AstraZeneca PLC
$172.48
+0.48%
HEALTHCARE · Cap: $261.94B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 18370416% more annual revenue ($60.44B vs $329,000). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ABOS
Avoid28
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABOS.
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$172.48
$21.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABOS
The strongest argument for ABOS centers on Price/Book.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ABOS
The primary concerns for ABOS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ABOS profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ABOS carries more volatility with a beta of 0.34 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Acumen Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?